BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26057181)

  • 1. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
    Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Varsseveld NC; van Bunderen CC; Ubachs DH; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1104-12. PubMed ID: 25574793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
    Olsson DS; Buchfelder M; Schlaffer S; Bengtsson BA; Jakobsson KE; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2009 Nov; 161(5):663-9. PubMed ID: 19734242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
    Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
    J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of growth hormone on pituitary tumour growth.
    Herring R; Russell-Jones D
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):365-8. PubMed ID: 20498595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Bunderen CC; van Varsseveld NC; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Eur J Endocrinol; 2014 Dec; 171(6):717-26. PubMed ID: 25227133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.
    Losa M; Gatti E; Rossini A; Lanzi R
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):75-8. PubMed ID: 19020392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
    Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
    Gasco V; Caputo M; Cambria V; Beccuti G; Caprino MP; Ghigo E; Maccario M; Grottoli S
    Endocrine; 2019 Feb; 63(2):341-347. PubMed ID: 30341707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database.
    Gardner CJ; Mattsson AF; Daousi C; Korbonits M; Koltowska-Haggstrom M; Cuthbertson DJ
    Eur J Endocrinol; 2015 Apr; 172(4):371-81. PubMed ID: 25583905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy.
    Ragnar Agnarsson H; Johannsson G; Ragnarsson O
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1479-85. PubMed ID: 24423362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
    Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
    Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
    Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
    J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study.
    Buchfelder M; Kann PH; Wüster C; Tuschy U; Saller B; Brabant G; Kleindienst A; Nomikos P;
    Eur J Endocrinol; 2007 Aug; 157(2):149-56. PubMed ID: 17656592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of each anterior pituitary hormone deficiency to the size of non-functioning pituitary adenoma in the hospitalized patients.
    Mukai K; Kitamura T; Tamada D; Murata M; Otsuki M; Shimomura I
    Endocr J; 2016 Nov; 63(11):965-976. PubMed ID: 27534814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.